Patent · US Active

Pharmaceutical composition comprising EDA-1 Fusion Protein

US8895003B2 · kind B2 · utility

2Cited by

5References

15Claims

0Family size

Assignee

Topotarget Switzerland SA · CH

Inventors

Olivier Gaide · Lausanne, CH
Pascal Schneider · Épalinges, CH
Jurg Tschopp · Épalinges, CH

Key dates

Filing date	Jun 20, 2013
Grant date	Nov 25, 2014
Priority date	—
Expiry date	Jun 20, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.